Ensure Patient Safety When Naming Biological Medications
By David Charles, MD and Mary Ann Chapman, PhD If requiring biological medications to have unique names would help ensure patient safety, wouldn’t it be an important convention to implement? The United States Food and Drug Administration (FDA) and several other organizations are currently considering requirements for naming biological medications—those often produced from cells or […]
The True Costs of Health Plan Specialty Tiers
By David Charles, MD and Mary Ann Chapman, PhD An important but rarely asked question is whether it costs more to fill prescriptions for needed medications than to fail to fill these prescriptions. Last year the Congressional Budget Office (CBO) released a memo entitled Offsetting Effects of Prescription Drug Use on Medicare’s Spending for Medical […]
